ATXS and BCRX Related Headlines
Go Back- Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
- BioCryst Pharma (BCRX) PT Raised to $26 at Cantor Fitzgerald After Astria (ATXS) Acquisition
- Oppenheimer Downgrades Astria Therapeutics (ATXS) to Perform
- BioCryst to acquire Astria Therapeutics for $920 million
- BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
ATXS and BCRX Related Press Releases
Go Back- Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
- BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
